No Data
Wakamoto Pharmaceutical: Half Year Report - Term 130 (2024/04/01 - 2025/03/31)
JFE revises down to 160 billion yen from 260 billion yen for the third quarter.
JFE <5411> announced a revision to the financial estimates for the fiscal year ending March 2025. The sales revenue was revised downward from 5 trillion 240 billion yen to 4 trillion 970 billion yen, and the operating profit was revised downward from 260 billion yen to 160 billion yen. In the iron & steel business, due to the rise in construction costs in the domestic building materials sector and labor shortages, further demand deceleration is expected, as well as stagnation in demand for Asia-bound steel for automobiles, resulting in a standalone crude steel production volume of around 22.4 million tons, which is 0.6 million tons lower than the previous outlook. [Positive Rating] <9001>
Wakamoto Pharmaceutical 1H Parent Loss Y141.00M Vs Loss Y222.00M
Wakamoto Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (unconsolidated)
Toyota, Itochu, NYK Line, Nitori Holdings (6th)
※The above calendar is only a schedule and may be subject to change depending on the company's circumstances.---------------------------------------November 6th (Wed) <1301> Kyokuyo <1332> Nissui <1420> Sanyo H <165A> SBI Leos <1799> Daiichi Construction <1814> Oomatsu Ken <1884> Nichi Doro <1898> Seiki Tokyu <196
Line Yahoo, Mitsubishi Heavy, nintendo co ltd, Kawasaki ship (5th)
※The above calendar is just a schedule and may be subject to change depending on the company's convenience.---------------------------------------November 5th (Tuesday)＜1723＞Nihondenki＜1787＞Nakabotech＜1826＞Satakensha＜1945＞Tokyo Enesis＜1967＞Yamato＜2222＞Kotobuki Spirits＜2281＞Prima Ham＜2372＞Ayro inc